Biotech’s Surge and the Investor’s Exit

by

Stonepine Capital Management disclosed the sale of 250,000 shares of Indivior PLC (INDV +0.14%) in a November 13 SEC filing, reducing its stake by approximately $2.75 million. This action followed a third-quarter transaction that lowered the fund’s Indivior holding to 100,000 shares valued at $2.41 million.

Context of the Sale

The transaction, detailed in the SEC filing, reflects a strategic adjustment. Stonepine’s exposure to Indivior now constitutes 1.96% of its reportable assets under management, down from 5.06% in the prior quarter. This shift aligns with broader portfolio reallocations, as the fund maintains significant positions in other biotech firms.

Portfolio Dynamics

After the sale, Stonepine’s top holdings include NASDAQ:VSTM ($23.58 million), NASDAQ:ADMA ($10.83 million), and NASDAQ:EOLS ($9.43 million). These allocations underscore the fund’s focus on smaller-cap biotech entities, where growth potential often outpaces market volatility.

Indivior’s shares have risen 194% over the past year, far exceeding the S&P 500’s 15% gain. At $36.21, the stock’s market capitalization stands at $4.53 billion, with trailing twelve-month revenue of $1.18 billion and net income of $124 million.

Company Fundamentals

Indivior specializes in opioid-use disorder treatments, including SUBLOCADE and SUBOXONE. Its revenue model relies on branded pharmaceuticals, with a focus on long-acting injectables and sublingual formulations. The company’s operations are concentrated in the U.S., with expanding international reach.

Recent financials show robust performance: $314 million in third-quarter revenue, a 15% year-over-year increase in SUBLOCADE sales, and a 14% rise in adjusted EBITDA to $120 million. Management has raised full-year 2025 guidance, projecting $1.18 billion to $1.22 billion in revenue and up to $420 million in adjusted EBITDA.

Strategic Implications

The sale by Stonepine suggests a recalibration of risk rather than a loss of confidence. While Indivior’s fundamentals are improving, the decision to trim shares reflects the inherent challenges of sustaining hypergrowth in a sector prone to regulatory and market shifts. The company’s future success hinges on maintaining cost discipline and executing its expansion plans beyond 2025.

Glossary

13F reportable AUM: Assets managed by institutions required to disclose holdings quarterly. AUM: Total value of investments under management. Net position change: The shift in share value after a transaction. Top holdings: Largest portfolio investments. Quarter-end: Final day of a fiscal quarter. Branded pharmaceutical products: Trademarked medications. Long-acting injectable therapies: Extended-release injections. Sublingual formulations: Medications absorbed under the tongue. Opioid use disorder: Chronic condition requiring medical intervention. Pipeline assets: Experimental treatments in development. TTM: Trailing twelve months.

📈

Read More

2025-12-28 20:42